TRDMT1 and osteosarcoma: It was also reported that DNMT2/TRDMT1, a writer of RNA m5C at sites of DNA damage, is required for efficient homologous recombination (HR) and provided resistance of U-2 OS osteosarcoma cells to radiotherapy and PARP inhibitors [23].